Astec LifeSciences Management

Management criteria checks 2/4

Astec LifeSciences' CEO is Anurag Roy, appointed in Jul 2021, has a tenure of 2.75 years. total yearly compensation is ₹29.41M, comprised of 89.7% salary and 10.3% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth ₹1.35M. The average tenure of the management team and the board of directors is 2.8 years and 6.3 years respectively.

Key information

Anurag Roy

Chief executive officer

₹29.4m

Total compensation

CEO salary percentage	89.7%
CEO tenure	2.8yrs
CEO ownership	0.006%
Management average tenure	2.8yrs
Board average tenure	6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Anurag Roy's remuneration changed compared to Astec LifeSciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-₹509m
Sep 30 2023	n/a	n/a	-₹258m
Jun 30 2023	n/a	n/a	₹60m
Mar 31 2023	₹29m	₹26m	₹256m
Dec 31 2022	n/a	n/a	₹736m
Sep 30 2022	n/a	n/a	₹975m
Jun 30 2022	n/a	n/a	₹883m
Mar 31 2022	₹16m	₹15m	₹899m

Compensation vs Market: Anurag's total compensation ($USD352.49K) is above average for companies of similar size in the Indian market ($USD186.77K).

Compensation vs Earnings: Anurag's compensation has increased whilst the company is unprofitable.

CEO

Anurag Roy (49 yo)

2.8yrs

Tenure

₹29,406,000

Compensation

Mr. Anurag Roy serves as Chief Executive Officer and Whole Time Director at Astec LifeSciences Limited since July 28, 2021. He served as Growth Unit Head of Advance Intermediates & Vitamins at Jubilant Org...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Anurag Roy	CEO & Whole Time Director	2.8yrs	₹29.41m	0.0056% ₹ 1.3m
Krishnamurthy Suryanarayan	Chief Financial Officer	less than a year	no data	no data
Arijit Mukherjee	Chief Operating Officer	2.8yrs	₹5.02m	no data
Tejashree Pradhan	Company Secretary & Compliance Officer	5.4yrs	₹1.90m	no data
C. Kirubasekaran	Vice President of Marketing	no data	no data	no data

2.8yrs

Average Tenure

50yo

Average Age

Experienced Management: 533138's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Anurag Roy	CEO & Whole Time Director	2.8yrs	₹29.41m	0.0056% ₹ 1.3m
Nadir Godrej	Non-Executive Chairman	8.5yrs	no data	no data
Balram Yadav	Non-Executive Non-Independent Director	8.5yrs	no data	no data
Ashok Hiremath	Non-Executive Non-Independent Director	30.3yrs	₹25.42m	1.99% ₹ 476.6m
Vijay Khot	Non-Executive Independent Director	8.3yrs	₹700.00k	no data
Brahma Vyas	Non-Executive Independent Director	8.3yrs	₹700.00k	no data
Rishinaradamangalam Govindan	Non-Executive Independent Director	4.3yrs	₹1.05m	no data
Nandkumar Dhekne	Non-Executive Independent Director	3.3yrs	₹400.00k	no data
Anjali Gupte	Non-Executive Independent Director	3.3yrs	₹300.00k	no data
Burjis Godrej	Additional Non-Executive Non- Independent Director	1.8yrs	no data	no data

6.3yrs

Average Tenure

67yo

Average Age

Experienced Board: 533138's board of directors are considered experienced (6.3 years average tenure).

Astec LifeSciences Management

Management criteria checks 2/4

Key information

Recent management updates

Non-Executive Non-Independent Director recently sold ₹4.8m worth of stock

High number of new directors

Astec Lifesciences Limited Announces Appointment of Mr. Madhur Gundecha as the Chief Financial Officer

Astec LifeSciences Limited Announces the Resignation of Saurav Bhala as Chief Financial Officer

High number of new directors

Astec Lifesciences Limited Appoints Burjis Godrej as an Additional, Non-Executive, Non- Independent Director

Recent updates

Astec LifeSciences Limited to Report Q4, 2024 Results on May 02, 2024

Price target decreased by 14% to ₹1,108

Price target decreased by 9.3% to ₹1,205

Third quarter 2024 earnings released: ₹12.41 loss per share (vs ₹0.43 profit in 3Q 2023)

Astec LifeSciences Limited to Report Q3, 2024 Results on Jan 25, 2024

Second quarter 2024 earnings released: ₹6.85 loss per share (vs ₹9.34 profit in 2Q 2023)

Astec LifeSciences Limited to Report Q2, 2024 Results on Oct 27, 2023

Astec LifeSciences Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Astec LifeSciences Limited to Report Q1, 2024 Results on Jul 27, 2023

Upcoming dividend of ₹1.50 per share at 0.1% yield

Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)

Non-Executive Non-Independent Director recently sold ₹4.8m worth of stock

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable by August 1, 2023

Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)

Investor sentiment improves as stock rises 26%

Third quarter 2023 earnings released: EPS: ₹0.43 (vs ₹12.63 in 3Q 2022)

Astec LifeSciences Limited to Report Q3, 2023 Results on Jan 30, 2023

Price target decreased to ₹1,923

High number of new directors

Second quarter 2023 earnings released: EPS: ₹9.34 (vs ₹4.63 in 2Q 2022)

Astec Lifesciences Limited Announces Appointment of Mr. Madhur Gundecha as the Chief Financial Officer

Astec LifeSciences Limited to Report Q2, 2023 Results on Oct 28, 2022

Investor sentiment improved over the past week

Astec LifeSciences Limited Announces the Resignation of Saurav Bhala as Chief Financial Officer

Price target increased to ₹2,132

High number of new directors

Astec Lifesciences Limited Appoints Burjis Godrej as an Additional, Non-Executive, Non- Independent Director

Astec LifeSciences Limited to Report Q1, 2023 Results on Jul 25, 2022

Upcoming dividend of ₹1.50 per share

Full year 2022 earnings: Revenues exceed analyst expectations

Price target increased to ₹1,869

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

MD & Director recently bought ₹37m worth of stock

Astec LifeSciences Limited Announces Cessation of Ashok Hiremath as the Managing Director of the Company

Non-Executive Non-Independent Director recently bought ₹1.5m worth of stock

Non-Executive Non-Independent Director recently bought ₹1.5m worth of stock

Non-Executive Non-Independent Director recently bought ₹3.5m worth of stock

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹1.5m worth of stock

Investor sentiment improved over the past week

Insider recently sold ₹2.4m worth of stock

Price target increased to ₹1,508

Price target increased to ₹1,386

Upcoming dividend of ₹1.50 per share

Full year 2021 earnings released: EPS ₹33.23 (vs ₹24.29 in FY 2020)

Whole Time Director recently sold ₹2.9m worth of stock

Investor sentiment improved over the past week

MD & Director recently sold ₹240m worth of stock

Full year 2021 earnings released: EPS ₹33.23 (vs ₹24.29 in FY 2020)

Astec Lifesciences Limited Recommends Final Dividend for the Year Ended March 31, 2021, Payable on August 6, 2021

Price target decreased to ₹1,221

Astec LifeSciences Limited to Report Q3, 2021 Results on Jan 25, 2021

New 90-day high: ₹1,194

MD & Director recently sold ₹440m worth of stock

New 90-day low: ₹986

MD & Director recently sold ₹527m worth of stock

First half earnings released

MD & Director recently sold ₹57m worth of stock

MD & Director recently sold ₹15.2m worth of stock

New 90-day high: ₹1,271

MD & Director recently sold ₹11.3m worth of stock

New 90-day high - ₹1,254

MD & Director recently sold ₹32.9m worth of stock

Astec LifeSciences Limited to Report Q1, 2021 Results on Jul 22, 2020

CEO Compensation Analysis

CEO